Soluble beta-amyloid precursor protein is related to disease progression in amyotrophic lateral sclerosis.
<h4>Background</h4>Biomarkers of disease progression in amyotrophic lateral sclerosis (ALS) could support the identification of beneficial drugs in clinical trials. We aimed to test whether soluble fragments of beta-amyloid precursor protein (sAPPα and sAPPß) correlated with clinical sub...
Guardado en:
Autores principales: | Petra Steinacker, Lubin Fang, Jens Kuhle, Axel Petzold, Hayrettin Tumani, Albert C Ludolph, Markus Otto, Johannes Brettschneider |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/94ad481f6bee4590b1b06b31be85e362 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
CSF concentrations of cAMP and cGMP are lower in patients with Creutzfeldt-Jakob disease but not Parkinson's disease and amyotrophic lateral sclerosis.
por: Patrick Oeckl, et al.
Publicado: (2012) -
Amyotrophic lateral sclerosis and frontotemporal degeneration
Publicado: (2000) -
The cortical signature of amyotrophic lateral sclerosis.
por: Federica Agosta, et al.
Publicado: (2012) -
Abnormal RNA stability in amyotrophic lateral sclerosis
por: E. M. Tank, et al.
Publicado: (2018) -
Current and emerging treatments for amyotrophic lateral sclerosis
por: Stefano Zoccolella, et al.
Publicado: (2009)